Patents Assigned to Nippon Shinyaku Company Ltd.
  • Patent number: 9340516
    Abstract: Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and a method of producing the crystal are provided. The Form-II crystal exhibits diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2? when the spectrum is obtained by using Cu K? radiation: 9.0 degrees, 12.9 degrees, 20.7 degrees, and 22.6 degrees. The Form-II crystal can be produced by crystallizing the subject compound from an alcoholic solvent, a ketone solvent, a saturated hydrocarbon solvent, an ether solvent, water, or a mixture of these solvents. The crystal may be administered as an active ingredient to a subject for the purpose of treating or preventing certain diseases, disorders, and symptoms, or for promoting angiogenesis or gene therapy.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: May 17, 2016
    Assignee: NIPPON SHINYAKU COMPANY, LTD.
    Inventor: Hideyuki Itou
  • Patent number: 5705188
    Abstract: This invention has for its object to insure an effective utilization of single-stranded nucleic acid copolymers, particularly poly(adenylic acid-uridylic acid), and to provide a pharmaceutical composition having antitumor activity.The invention typically relates to a pharmaceutical composition comprising a lipid device such as Lipofectin (trademark), 3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleylgycerol, 3-O-(2-dimethylamino-ethyl)carbamoyl-1,2-O-dioleylglycerol, 3-O-(2-diethylaminoethyl) carbamoyl-1,2-O-dioleylgycerol, or 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and poly(adenylic acid-uridylic acid).
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: January 6, 1998
    Assignee: Nippon Shinyaku Company, Ltd.
    Inventors: Yano Junichi, Tadaaki Ohgi
  • Patent number: 4336373
    Abstract: Bis(2-hydroxymethyl-3,4,5-trihydroxypiperidine-1-yl-propenyl) compounds and their acid addition salts are antihyperglycemic agents. Typical examples are 1,4-bis[3-(2-hydroxymethyl-3,4,5-trihydroxypiperidin-1-yl)prop-2-enyl] benzene and 1,3-bis-{4-[3-(2-hydroxymethyl-3,4,5-trihydroxy-piperidin-1-yl)prop-2-enyl ]phenoxy}propane.
    Type: Grant
    Filed: March 26, 1981
    Date of Patent: June 22, 1982
    Assignee: Nippon Shinyaku Company, Ltd.
    Inventors: Shingo Matsumura, Hiroshi Enomoto, Yoshiaki Aoyagi, Yoshiaki Yoshikuni, Masahiro Yagi, Kohei Kura, Ichiro Shirahase
  • Patent number: RE30886
    Abstract: 2-Hydroxymethyl-3,4,5-trihydroxypiperidine possesses antidiabetic and lipid biosynthesis inhibitory properties. The use of the compound for such indications and pharmaceutical compositions adapted to this use are described.
    Type: Grant
    Filed: December 15, 1978
    Date of Patent: March 23, 1982
    Assignee: Nippon Shinyaku Company Ltd.
    Inventors: Katsuya Ohata, Hiroshi Enomoto, Yoshiaki Yoshikuni, Tatsuhiko Kono, Masahiro Yagi